Please use this identifier to cite or link to this item:
https://www.um.edu.mt/library/oar/handle/123456789/119945
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Petrie, John R. | - |
dc.contributor.author | Adler, A. | - |
dc.contributor.author | Vella, Sandro | - |
dc.date.accessioned | 2024-03-15T13:47:59Z | - |
dc.date.available | 2024-03-15T13:47:59Z | - |
dc.date.issued | 2011 | - |
dc.identifier.citation | Petrie, J. R., Adler, A., & Vella, S. (2011). What to add in with metformin in type 2 diabetes? QJM: An International Journal of Medicine, 104(3), 185-192. | en_GB |
dc.identifier.uri | https://www.um.edu.mt/library/oar/handle/123456789/119945 | - |
dc.description.abstract | This review considers the therapeutic choices currently faced by people with type 2 diabetes and those caring for them when glucose levels initially controlled with lifestyle management and metformin start to rise. While sulphonylureas are familiar agents and cheaper than other alternatives, they cause hypoglycaemia and modest weight gain, and robust outcome data are still lacking. Dipeptidyl peptidase 4 inhibitors (‘gliptins’) have an attractive pharmacological and adverse effect profile, but their effects on the cardiovascular system are also uncertain. Thiazolidinediones (‘glitazones’) are effective glucose-lowering agents, but cause weight gain and increase the risk of fracture, while the cardiovascular benefits hoped for in association with ‘insulin-sensitization’ have not been as expected. Glucagon-like peptide-1 agonists will not be acceptable as initial second-line agents for many people as they are injectable rather than oral. Well-powered ‘head-to-head’ clinical trials of adequate duration are therefore required to allow evidence-based decisions on second-line therapy. | en_GB |
dc.language.iso | en | en_GB |
dc.publisher | Oxford University Press | en_GB |
dc.rights | info:eu-repo/semantics/openAccess | en_GB |
dc.subject | Metformin | en_GB |
dc.subject | Type 2 diabetes | en_GB |
dc.subject | Hypoglycemia | en_GB |
dc.subject | Clinical trials | en_GB |
dc.title | What to add in with metformin in type 2 diabetes? | en_GB |
dc.type | article | en_GB |
dc.rights.holder | The copyright of this work belongs to the author(s)/publisher. The rights of this work are as defined by the appropriate Copyright Legislation or as modified by any successive legislation. Users may access this work and can make use of the information contained in accordance with the Copyright Legislation provided that the author must be properly acknowledged. Further distribution or reproduction in any format is prohibited without the prior permission of the copyright holder. | en_GB |
dc.description.reviewed | peer-reviewed | en_GB |
dc.identifier.doi | 10.1093/qjmed/hcq237 | - |
dc.publication.title | QJM: An International Journal of Medicine | en_GB |
Appears in Collections: | Scholarly Works - FacM&SMed |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
What_to_add_in_with_metformin_in_type_2_diabetes_2011.pdf | 119.54 kB | Adobe PDF | View/Open |
Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.